Feature-tracking Cardiac Magnetic Resonance Method: a Valuable Marker of Replacement Fibrosis in Hypertrophic Cardiomyopathy

Overview

Journal Pol J Radiol

Publisher Termedia

Specialty Radiology

Date 2022 Jul 1

PMID 35774218

Authors

Nahid Rezaeian

Leila Hosseini

Negar Omidi

Mahya Khaki

Homa Najafi

Kianoosh Kasani

Mostafa Mousavizadeh

Yasaman Khalili

Mohammad Mehdi Hemmati Komasi

Yaser Toloueitabar

Sanaz Asadian

Affiliations

Soon will be listed here.

Abstract

Purpose: Left ventricular (LV) replacement fibrosis is a marker of adverse cardiac events in hypertrophic cardiomyopathy (HCM). We aimed to assess the efficacy of the feature-tracking cardiac magnetic resonance (FT-CMR) in the detection of LV replacement fibrosis.

Material And Methods: Fifty-one patients with HCM (51% female, mean age = 21 ± 5.2 years) and significant myocardial hypertrophy, who underwent CMR between February 2018 and December 2019 were enrolled. Functional and 3D FT-CMR parameters were measured. LV global longitudinal strain, global radial strain (GRS), and global circumferential strain (GCS) were recorded. The percentage of enhanced myocardial mass was calculated. Univariate and multivariate regression analyses were performed to determine the predictors of fibrosis. A -value of less than 0.05 was considered significant.

Results: The mean enhanced mass percentage was 15.2 ± 10.53%. Among LV volumetric parameters, end-systolic and end-diastolic volume indices predicted fibrosis (fitness [F] = 8.11 and = 0.006 vs. = 6.6 and = 0.012, correspondingly). The univariate linear regression demonstrated that GCS and GRS predicted total enhanced mass (%) ( = 12.29 and = 0.001 vs. = 7.92 and = 0.007, respectively). After the inclusion of all volumetric and deformation parameters, the multivariate analysis identified the model of a combination of LV end-diastolic volume index (LV EDVI) and LV GCS as a robust predictor of the fibrosis percentage ( = 8.86 and = 0.005).

Conclusions: Non-contrast CMR parameters including LV GCS and LV EDVI are valuable markers of replacement fibrosis in HCM patients with notable myocardial hypertrophy.

Citing Articles

The predictive value of cardiac MRI strain parameters in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction and a low fibrosis burden: a retrospective cohort study.

Salmanipour A, Ghaffari Jolfayi A, Sabet Khadem N, Rezaeian N, Chalian H, Mazloomzadeh S Front Cardiovasc Med. 2023; 10:1246759.

PMID: 37781305 PMC: 10533925. DOI: 10.3389/fcvm.2023.1246759.

References

Bogarapu S, Puchalski M, Everitt M, Williams R, Weng H, Menon S . Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy. Pediatr Cardiol. 2016; 37(4):663-73. DOI: 10.1007/s00246-015-1329-8. View

Ommen S, Mital S, Burke M, Day S, Deswal A, Elliott P . 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142(25):e558-e631. DOI: 10.1161/CIR.0000000000000937. View

Reichek N, Gupta D . Hypertrophic cardiomyopathy: cardiac magnetic resonance imaging changes the paradigm. J Am Coll Cardiol. 2008; 52(7):567-8. DOI: 10.1016/j.jacc.2008.05.014. View

Rezaeian N, Mohtasham M, Khaleel A, Parnianfard N, Kasani K, Golshan R . Comparison of global strain values of myocardium in beta-thalassemia major patients with iron load using specific feature tracking in cardiac magnetic resonance imaging. Int J Cardiovasc Imaging. 2020; 36(7):1343-1349. DOI: 10.1007/s10554-020-01835-3. View

Hen Y, Iguchi N, Utanohara Y, Takada K, Machida H, Takayama M . Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circ J. 2014; 78(4):929-37. DOI: 10.1253/circj.cj-13-0979. View

Bruder O, Wagner A, Jensen C, Schneider S, Ong P, Kispert E . Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56(11):875-87. DOI: 10.1016/j.jacc.2010.05.007. View

Jafari F, Maddah Safaei A, Hosseini L, Asadian S, Kamangar T, Zadehbagheri F . The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review. Heart Fail Rev. 2020; 26(3):679-697. DOI: 10.1007/s10741-020-10028-y. View

Voigt J, ARNOLD M, Karlsson M, Hubbert L, Kukulski T, Hatle L . Assessment of regional longitudinal myocardial strain rate derived from doppler myocardial imaging indexes in normal and infarcted myocardium. J Am Soc Echocardiogr. 2000; 13(6):588-98. DOI: 10.1067/mje.2000.105631. View

Mikami Y, Kolman L, Joncas S, Stirrat J, Scholl D, Rajchl M . Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2014; 16:85. PMC: 4189726. DOI: 10.1186/s12968-014-0085-x. View

10.

Chan R, Maron B, Olivotto I, Pencina M, Assenza G, Haas T . Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014; 130(6):484-95. DOI: 10.1161/CIRCULATIONAHA.113.007094. View

11.

Maron M . Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012; 14:13. PMC: 3293092. DOI: 10.1186/1532-429X-14-13. View

12.

She J, Guo J, Yu Y, Zhao S, Chen Y, Ge M . Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy: The Utility of Myocardial Strain Based on Cardiac MR Tissue Tracking. J Magn Reson Imaging. 2020; 53(1):51-60. DOI: 10.1002/jmri.27307. View

13.

Spiewak M, Klopotowski M, Ojrzynska N, Petryka-Mazurkiewicz J, Milosz-Wieczorek B, Mazurkiewicz L . Impact of cardiac magnetic resonance on the diagnosis of hypertrophic cardiomyopathy - a 10-year experience with over 1000 patients. Eur Radiol. 2020; 31(3):1194-1205. PMC: 7880911. DOI: 10.1007/s00330-020-07207-8. View

14.

Petersen S, Khanji M, Plein S, Lancellotti P, Bucciarelli-Ducci C . European Association of Cardiovascular Imaging expert consensus paper: a comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity. Eur Heart J Cardiovasc Imaging. 2019; 20(12):1321-1331. DOI: 10.1093/ehjci/jez232. View

15.

Smith B, Dorfman A, Yu S, Russell M, Agarwal P, Mahani M . Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy. Am J Cardiol. 2014; 113(7):1234-9. DOI: 10.1016/j.amjcard.2013.12.034. View

16.

Serri K, Reant P, Lafitte M, Berhouet M, Le Bouffos V, Roudaut R . Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006; 47(6):1175-81. DOI: 10.1016/j.jacc.2005.10.061. View

17.

Pennell D . Cardiovascular magnetic resonance. Circulation. 2010; 121(5):692-705. DOI: 10.1161/CIRCULATIONAHA.108.811547. View

18.

Cerqueira M, Weissman N, Dilsizian V, Jacobs A, Kaul S, Laskey W . Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002; 105(4):539-42. DOI: 10.1161/hc0402.102975. View

19.

Elliott P, Anastasakis A, Borger M, Borggrefe M, Cecchi F, Charron P . 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39):2733-79. DOI: 10.1093/eurheartj/ehu284. View

20.

Liu D, Ma X, Liu J, Zhao L, Chen H, Xu L . Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine. Int J Cardiovasc Imaging. 2017; 33(8):1191-1200. DOI: 10.1007/s10554-017-1101-7. View